Iluria

Biomarker-based ADHD Monitoring

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in August 2018 by hagay levy and Birkat Klimshtein Levy, Iluria operates with 11–50 employees. The company has raised $2.04M across 5 funding rounds from 2 investors. In May 2022, Iluria secured a grant of $460K.

Business overview

Iluria develops a clinically proven software solution for in-depth, continuous, and passive monitoring of ADHD using commercial smart wearables. The technology detects ADHD-related patterns to assess treatment effectiveness, enabling personalized and accurate care. Iluria serves the health tech and life sciences sector, providing solutions for parents, doctors, and healthcare providers, with a focus on mental health, wellness, and digital healthcare.

Log in to access full profile

Company Intelligence Q&A

What is Iluria's core technology?
Iluria utilizes a software solution that provides continuous and passive monitoring through commercial smart wearables. This technology detects patterns related to ADHD, enabling personalized and accurate care.
When was Iluria founded and by whom?
Iluria was founded in August 2018 by hagay levy and Birkat Klimshtein Levy.
Which organizations has Iluria partnered with for clinical trials?
Iluria has completed two successful clinical trials with the Cincinnati Children's Hospital Medical Center and Clalit Health Services.
What is Iluria's total capital raised and number of funding rounds?
Iluria has raised a total of $2.04M across 5 funding rounds, with the latest being a $460K grant in May 2022.
Log in to access full profile